Tech Company Financing Transactions
Spiral Therapeutics Funding Round
Esperante Ventures and Ferring Ventures joined a funding round for Spiral Therapeutics. This VC investment round closed on 8/30/2023.
Transaction Overview
Company Name
Announced On
8/30/2023
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
Esperante Ventures (Lead Investor) (Dean Slagel)
Proceeds Purpose
The company intends to use the funds to accelerate its development efforts to treat inner ear disorders, including the collection of additional clinical data for its lead program SPT-2101 for Meniere's Disease, and to advance its hearing loss pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6000 Shoreline Ct, Suite 206, South
San Francisco,, CA 94080
USA
San Francisco,, CA 94080
USA
Phone
Website
Email Address
Overview
Spiral is advancing a therapeutic pipeline with focus on balance disorders and hearing loss. Our lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Ménière's disease. 40 million people in the US qualify for hearing loss treatment, but there are no drugs approved for hearing loss. Drug delivery to the inner ear remains the largest obstacle. Precise, non-invasive placement techniques, combined with long-acting delivery systems have the potential to overcome the barriers of drug delivery to the inner ear.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/30/2023: QuantHealth venture capital transaction
Next: 8/30/2023: Impulse Space venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs